{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T13:18:56Z","timestamp":1790255936543,"version":"4.1.0"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,12,19]],"date-time":"2018-12-19T00:00:00Z","timestamp":1545177600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.ejca.2018.12.006","type":"journal-article","created":{"date-parts":[[2019,1,14]],"date-time":"2019-01-14T09:28:35Z","timestamp":1547458115000},"page":"69-77","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"special_numbering":"C","title":["The efficacy and safety of sunitinib given on an individualised schedule as first-line therapy for metastatic renal cell carcinoma: A phase 2 clinical trial"],"prefix":"10.1016","volume":"108","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6903-5357","authenticated-orcid":false,"given":"Georg A.","family":"Bjarnason","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer J.","family":"Knox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian K.","family":"Kollmannsberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Soulieres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. Scott","family":"Ernst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pawel","family":"Zalewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina M.","family":"Canil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Winquist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastien J.","family":"Hotte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott A.","family":"North","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel Yick Chin","family":"Heng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robyn Jane","family":"Macfarlane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter M.","family":"Venner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil","family":"Kapoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron R.","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard J.","family":"Eigl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Czaykowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Boyd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naveen S.","family":"Basappa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ejca.2018.12.006_bib1","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s00280-009-1170-y","article-title":"Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic\/pharmacodynamic meta-analysis","volume":"66","author":"Houk","year":"2010","journal-title":"Cancer Chemother Pharmacol"},{"issue":"14","key":"10.1016\/j.ejca.2018.12.006_bib2","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1517\/14656566.8.14.2359","volume":"8","author":"Sunitinib","year":"2007","journal-title":"Expert Opin Pharmacother"},{"issue":"4","key":"10.1016\/j.ejca.2018.12.006_bib3","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.urolonc.2013.10.004","article-title":"Outcomes in patients with metastatic renal cell cancer treated with individualized sunitinib therapy: correlation with dynamic microbubble ultrasound data and review of the literature","volume":"32","author":"Bjarnason","year":"2014","journal-title":"Urol Oncol"},{"issue":"10","key":"10.1016\/j.ejca.2018.12.006_bib4","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1172\/JCI24612","article-title":"Rapid vascular regrowth in tumors after reversal of VEGF inhibition","volume":"116","author":"Mancuso","year":"2006","journal-title":"J Clin Invest"},{"issue":"14","key":"10.1016\/j.ejca.2018.12.006_bib5","doi-asserted-by":"crossref","first-page":"3961","DOI":"10.1158\/1078-0432.CCR-12-0002","article-title":"Rapid angiogenesis onset after discontinuation of sunitinib treatment of renal cell carcinoma patients","volume":"18","author":"Griffioen","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"22","key":"10.1016\/j.ejca.2018.12.006_bib6","doi-asserted-by":"crossref","first-page":"3584","DOI":"10.1200\/JCO.2008.20.1293","article-title":"Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma","volume":"27","author":"Motzer","year":"2009","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.ejca.2018.12.006_bib7","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1200\/JCO.2011.36.4133","article-title":"Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma","volume":"30","author":"Motzer","year":"2012","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.ejca.2018.12.006_bib8","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1056\/NEJMoa1303989","article-title":"Pazopanib versus sunitinib in metastatic renal-cell carcinoma","volume":"369","author":"Motzer","year":"2013","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.ejca.2018.12.006_bib9","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1038\/bjc.2014.28","article-title":"Anti-VEGF therapy in mRCC: differences between Asian and non-Asian patients","volume":"110","author":"Wang","year":"2014","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2018.12.006_bib10","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.juro.2013.08.090","article-title":"Clinical outcomes for patients with metastatic renal cell carcinoma treated with alternative sunitinib schedules","volume":"191","author":"Atkinson","year":"2013","journal-title":"J Urol"},{"issue":"suppl","key":"10.1016\/j.ejca.2018.12.006_bib11","article-title":"Effects of pazopanib (PAZ) and sunitinib (SUN) dose modification on safety and efficacy in patients with metastatic renal cell carcinoma (mRCC) from COMPARZ","volume":"35","author":"Bjarnason","year":"2017","journal-title":"J Clin Oncol"},{"issue":"suppl 5","key":"10.1016\/j.ejca.2018.12.006_bib12","article-title":"A retrospective analysis of data from two trials of sunitinib in patients with advanced renal cell carcinoma: pitfalls of efficacy subgroup analyses based on dose-reduction status","volume":"30","author":"Khosravan","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2018.12.006_bib13","article-title":"Sunitinib dose-escalation after disease progression in metastatic renal cell carcinoma","author":"Raphael","year":"2017","journal-title":"Urol Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2018.12.006_bib14","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1200\/JCO.1993.11.3.570","article-title":"The functional assessment of cancer therapy scale: development and validation of the general measure","volume":"11","author":"Cella","year":"1993","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2018.12.006_bib15","first-page":"191","article-title":"Development and validation of the functional assessment of cancer therapy-kidney symptom index (FKSI)","volume":"4","author":"Cella","year":"2006","journal-title":"J Support Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2018.12.006_bib16","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1002\/cam4.302","article-title":"Impact of adverse events, treatment modifications, and dose intensity on survival among patients with advanced renal cell carcinoma treated with first-line sunitinib: a medical chart review across ten centers in five European countries","volume":"3","author":"Porta","year":"2014","journal-title":"Cancer Med"},{"issue":"13","key":"10.1016\/j.ejca.2018.12.006_bib17","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/S1470-2045(13)70465-0","article-title":"Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial","volume":"14","author":"Hutson","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2018.12.006_bib18","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ejca.2018.02.012","article-title":"Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): progression-free survival by independent review and overall survival update","volume":"94","author":"Choueiri","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2018.12.006_bib19","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma","author":"Motzer","year":"2018","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ejca.2018.12.006_bib20","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1080\/14737140.2017.1276830","article-title":"How clinical practice is changing the rules: the sunitinib 2\/1 schedule in metastatic renal cell carcinoma","volume":"17","author":"Bracarda","year":"2017","journal-title":"Expert Rev Anticancer Ther"},{"issue":"16","key":"10.1016\/j.ejca.2018.12.006_bib21","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1200\/JCO.2017.77.1485","article-title":"Phase II study of two weeks on, one week off sunitinib scheduling in patients with metastatic renal cell carcinoma","volume":"36","author":"Jonasch","year":"2018","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1016\/j.ejca.2018.12.006_bib22","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1200\/JCO.2016.71.1184","article-title":"A phase II study of intermittent sunitinib in previously untreated patients with metastatic renal cell carcinoma","volume":"35","author":"Ornstein","year":"2017","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2018.12.006_bib23","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/S1470-2045(18)30081-0","article-title":"Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial","volume":"19","author":"Atkins","year":"2018","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.ejca.2018.12.006_bib24","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1038\/bjc.2014.503","article-title":"Relationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinoma","volume":"111","author":"Suttle","year":"2014","journal-title":"Br J Cancer"},{"issue":"5","key":"10.1016\/j.ejca.2018.12.006_bib25","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1002\/jcph.73","article-title":"Axitinib in metastatic renal cell carcinoma: results of a pharmacokinetic and pharmacodynamic analysis","volume":"53","author":"Rini","year":"2013","journal-title":"J Clin Pharmacol"},{"issue":"13","key":"10.1016\/j.ejca.2018.12.006_bib26","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.1158\/1078-0432.CCR-17-2652","article-title":"Pazopanib exposure relationship with clinical efficacy and safety in the adjuvant treatment of advanced renal cell carcinoma","volume":"24","author":"Sternberg","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.ejca.2018.12.006_bib27","doi-asserted-by":"crossref","first-page":"e275","DOI":"10.1016\/j.clgc.2016.08.014","article-title":"Clinical effect of dose escalation after disease progression in patients with metastatic renal cell carcinoma","volume":"15","author":"Ornstein","year":"2016","journal-title":"Clin Genitourin Cancer"},{"issue":"6","key":"10.1016\/j.ejca.2018.12.006_bib28","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1111\/bju.13740","article-title":"Sorafenib dose escalation in treatment-naive patients with metastatic renal cell carcinoma: a non-randomised, open-label, Phase 2b study","volume":"119","author":"Gore","year":"2017","journal-title":"BJU Int"},{"issue":"suppl","key":"10.1016\/j.ejca.2018.12.006_bib29","article-title":"Prospective phase II multi-center study of individualized axitinib (Axi) titration for metastatic renal cell carcinoma (mRCC) after treatment with PD-1\/PD-L1 inhibitors","volume":"36","author":"Ornstein","year":"2018","journal-title":"J Clin Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804918315521?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804918315521?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:23:03Z","timestamp":1760732583000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804918315521"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":29,"alternative-id":["S0959804918315521"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2018.12.006","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The efficacy and safety of sunitinib given on an individualised schedule as first-line therapy for metastatic renal cell carcinoma: A phase 2 clinical trial","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2018.12.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}